GRI Bio, Inc.
GRI · XNASCIK 1824293fmd_0HBGA9SRBAFF6DK0SYNKB72DBQManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Jun 30, 2026, 26 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | – | – | – | – |
| Research and development | 4 | 5 | 0 | 3 | 4 | 7 |
| Total operating expenses | 5 | 9 | 2 | 11 | 8 | 12 |
| Operating income | (5) | (9) | (2) | (11) | (8) | (12) |
| Other non-operating income (expense) | 0 | 0 | 0 | 0 | 0 | – |
| Income tax expense | – | – | – | – | 0 | 0 |
| Net income | (5) | (9) | (3) | (13) | (8) | (12) |
| Net income to common shareholders | – | – | – | (13) | (10) | (12) |